<DOC>
	<DOCNO>NCT00506792</DOCNO>
	<brief_summary>This study investigate safety , tolerability , pharmacokinetic , pharmacodynamic response patient cystic fibrosis administration QAU145 via intranasal spray .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics QAU145 Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female ( woman must postmenopausal surgically sterile ) subject cystic fibrosis age 18 50 . Any presence seasonal nonseasonal allergy affect nose , nasal passage , throat sinus within 2 week prior dose . Any upper respiratory tract infection sign symptom within 2 week prior dose . Any presence nasal polyps structural abnormality , frequent history nose bleeding , recent nasal surgery ( within 12 week prior dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Cystic fibrosis , QAU145 , nasal potential difference</keyword>
</DOC>